nicotine replacement patches

Preclinical

nicotine replacement patches is one of 31 therapeutic programs targeting Smoking Cessation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Smoking CessationRecruiting

Smoking CessationPreclinical

Recruiting

Competition

Competitive Landscape

154 competitors in Smoking Cessation

#DrugCompanyPhaseTrials

Wellbutrin

GSK

Phase 3

5 2

Chantix

Pfizer

Phase 3

3 3

Ozempic

Novo Nordisk

Phase 3

2 4

Topamax

WWim Janssens

Phase 3

3 5

Rimonabant

Sanofi

Phase 3

5 6

Revia

Teva

Phase 2

2 7

Lopid

Pfizer

Phase 2

1 8

Pharmacotherapy

UUniversity of Pittsburgh

Phase 3

1 9

Standard Treatment

Boehringer Ingelheim

Phase 3

1 10

Zocor

OOrganon and Co

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Smoking Cessation

NCT07487818

Clinical

Trials by Indication[1]

Smoking Cessation1 trial

Using Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation

Recruiting·MMayo Clinic·Preclinical·NCT07487818·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for nicotine replacement patches. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for nicotine replacement patches. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: MMayo Clinic

nicotine replacement patches

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Smoking Cessation1 trial

References

Drug Info

Quick Facts

Related News